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myo-Inositol uptake was investigated in a murine neuroblastoma clone (NlE-115) to determine the effect 
of altered Na+,K+-ATPase activity. The Na+ ionophone monensin, and veratridine, an alkaloid affecting 
voltage-dependent Na+ entry, increased acute 22Na+ uptake and 22Na+ efflux from pre-loaded cells, con- 
comitant with enhanced myo-inositol uptake. This effect was also seen following insulin. Insulin-stimulated 
myo-inositol uptake was inhibited by amiloride, ouabain and pyrithiamine. ‘Amiloride inhibition suggests 
that activation of Na+/H+ exchange preceding Na+,K+-ATPase activation is involved in insulin stimula- 
tion of myo-inositol uptake. Pyrithiamine inhibition is an indication of prior activation of the Na+,K+- 
ATPase TV+ catalytic subunit by insulin. The results provide evidence that insulin contributes to the mainte- 
nance of Na+,K+-ATPase in neuronal tissue. 
myo-Inositol uptake; Na ‘; (Nat + K +)-ATPase; Insulin; Pyrithiamine; (Neuroblastoma clone) 
1. INTRODUCTION 
The cellular uptake of myo-inositol is dependent 
on Na+ flux maintained by Na+- and .Kf-depen- 
dent adenosine triphosphatase (Na+,K+-ATPase 
[ 11. This enzyme is the basis of active cellular 
transport of Na+ and K+ and specific subunits of 
the Na+- and K+-sensitive complex alter reactivity 
in response to ion concentration, phosphorylation 
state and plasma membrane environment [2-41. In 
diabetic neuropathy, there is considerable evidence 
to indicate that a defect in Na+,K+-ATPase in 
peripheral nerve, and autonomic ganglia, reflects 
an underlying alteration in cellular myo-inositol 
uptake [5,6]. The neuronal system therefore 
represents a very tightly coupled system, as the 
Na+ gradient generated by the action of 
Na+,K+-ATPase is required for the uptake of 
myo-inositol and subsequent formation of 
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phosphoinositides. The intracellular actions of 
phosphoinositide-derived, 1,2-diacylglycerol and 
inositol phosphates are thus limited by the 
availability of myo-inositol. To investigate possi- 
ble changes to Na+,K+-ATPase activity which may 
be involved in neuronal responses in diabetes, a 
murine neuroblastoma clone, NlE-115, was used. 
Recently, we have shown that cells of this clone 
respond in a very similar manner to peripheral 
motor nerve when Na+-dependent myo-inositol 
uptake is measured after a number of metabolic 
manipulations [7]. Altered NaC fluxes were in- 
duced in these cells to determine conditions under 
which Na+,K+-ATPase may be modified and the 
effect of this on myo-inositol uptake. In par- 
ticular, evidence was sought for an insulin- 
sensitive activation contributing to myo-inositol 
uptake. An auf-subunit of Na+,K+-ATPase has 
been described in a number of tissues including 
brain [8,9]. The complex containing this 
cu+-subunit is exclusively the insulin-sensitive form 
of Na+,K+-ATPase activity [lo]. Na’-pump activi- 
ty was stimulated by two means, rapidly by addi- 
84 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/87/$3.50 0 1987 Federation of European Biochemical Societies 
Volume 220, number 1 FEBS LETTERS August 1987 
tion of the Na+ ionophore, monensin, and more 
gradually by prolonged incubation with the 
alkaloid veratridine, stabilizing an open form of 
voltage-sensitive Na+ channels [ 111, which will 
recruit Na+,K+-ATPase activity to the cell mem- 
brane [ 121. Inhibition of Na+-pump activity was 
investigated using ouabain and with pyrithiamine, 
an anti-metabolite of thiamine with considerable 
specificity for the cY+-subunit contained in the 
Na+,K+-ATPase complex [ 131. Cellular myo- 
[2-3H]inositol uptake was determined concomitant 
with 22Na+ content. 
2. MATERIALS AND METHODS 
2.1. Culture of murine neuroblastoma cells 
(NIE-115) 
NlE-115 neuroblastoma cells, used at passage 
16-25, were a gift from Dr E. Richelson (Depart- 
ment of Psychiatry and Pharmacology, Mayo 
Clinic, Rochester, MN). The cells were grown at 
37°C in humidified air containing 5% CO2 in 
Dulbecco’s modification of minimum essential 
medium/fetal bovine serum (90: 10, v/v). Prior to 
experimentation, cells were subcultured and plated 
at a density of 1 x lo6 cells in Dulbecco’s 
medium/fetal bovine serum (90: 10, v/v) contain- 
ing glucose (5.6 or 25 mmol/l). 
2.2. myo-Inositol uptake 
myo-Inositol uptake was determined as in [7]. 
Briefly, cells were incubated in a modified buffer 
containing 135 mmol/l NaCl, 5.4 mmol/l KCl, 
1.2 mmol/l CaC12, 1 mmol/l NaH2P04, 1.3 
mmol/l MgS04 and 5 mmol/l Hepes, pH 7 (330 
mosmol/l) containing myo-[2-3H]inositol (4 x 
lo-’ mol/l, 10 &i/ml) for 20 min. 
At the end of this time, cells were removed, 
washed with three changes of medium or buffer 
without added radiolabelled myo-inositol, blotted 
and solubilized in 0.3 ml of 0.75 N NaOH at 80°C. 
myo-[2-3H]Inositol content was quantitated in a 
gel formed by the addition of 4 ml Hz0 and 10 ml 
pseudocumene scintillant .
In separate experiments labelled myo-inositol 
was replaced with 5 ,&i L-[ l-3H(N)]glucose (final 
L-glucose concentration 5 x 10’ mol/l) for deter- 
mination of non-specific uptake and entrapped ex- 
tracellular medium. 
2.3. 22Na+ content and efflux from NIE-115 cells 
Cells were incubated for 4 h in Dulbecco’s 
medium containing 23Na+ (149 mmol/l) and 22Na+ 
(22Na+ at final spec. act. 1 &i/ml). The incuba- 
tions were either continued for a further 20 min in 
the presence of added agents or the medium 
removed and replaced with medium containing 
23Na+ only for a further 20 min period. Cells were 
washed and solubilized as for myo-inositol deter- 
minations. 
2.4. Addition of agents 
When present, insulin, pyrithiamine, ouabain, 
monesin or amiloride, dissolved appropriately, 
were added either singly or in combination, for the 
last 20 min of incubation in Dulbecco’s medium or 
for 20 min of buffer incubation with either myo- 
[2-3H]inositol, or to cells pre-loaded for 4 h with 
22Na+. Veratridine was included for 40 h in 
culture. The solutions used for suspending the 
agents, H20, ethanol or dimethyl sulphoxide were 
included in control incubations. 
2.5. Cellular protein determinations 
Protein was determined on solubilized cell 
preparations using Coomassie brilliant blue dye 
[14]. myo-[3H]Inositol and 22Na+ content were 
corrected for extracellular content and expressed 
as pmol/lOO pg protein and nmol/lOO pg protein, 
respectively. 
2.6. Statistical analysis 
Data were analysed using the Student’s t-test for 
paired data, significance being taken at the 5% 
level @ < 0.05) unless indicated otherwise, 
3. RESULTS 
3.1. myo-Inositol uptake 
The results for myo-inositol uptake are sum- 
marized in table 1. When NlE-115 cells were 
cultured at two glucose concentrations, the results 
confirmed previous observations of inhibition of 
myo-inositol uptake in the presence of elevated 
glucose (4.01 f 0.17 vs 2.14 f 0.06 pmol/lOOpg 
protein at 5.6 and 25 mmol/l glucose, respective- 
ly). No effect of insulin was seen at the lower 
glucose concentration but a significant increase 
was seen with insulin in cells incubated at 
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Table 1 
myo-Inositol uptake in NIE-115 neuroblastoma cells 
Additions 
No pre-incubation 
Nil 
Ouabain (10m4 M) 
Pyrithiamine ( 10m5 M) 
Amiloride (10-s M) 
Monensin (1O-6 M) 
Veratridine (lo-’ M) 
5.6 mmol/l glucose 
No added Insulin 
insulin (0.7 nmol/l) 
4.01 f 0.17 4.12 k 0.27 
3.32 * 0.12” 3.41 * 0.12” 
3.78 t: 0.09 3.87 k 0.08 
3.71 !z 0.09 3.67 + 0.08 
4.79 * 0.14” _ 
4.51 + 0.16” _ 
25 mmol/l glucose 
No added Insulin 
insulin (0.7 nmol/l) 
2.14 k 0.06” 3.71 -t 0.04b 
1.31 * 0.04b 1.42 k 0.03“ 
1.89 + O.Ojb 1.91 t 0.04’ 
1.88 + 0.07b 1.89 + 0.02’ 
2.78 & 0.08b - 
2.89 k 0.08b - 
Pre-incubation; veratridine ( 10m5 M) 
Nil 
Ouabain (10m4 M) 
Pyrithiamine (1 O-’ M) 
6.61 & 0.27b _ 
3.90 t 0.24b _ 
4.89 k 0.24b _ 
a Significantly different from incubation in the presence of 5.6 mmol/l glucose without additions 
b Significantly different from incubation in the presence of 25 mmol/l glucose without additions 
’ Significantly different from incubation in the presence of 25 mmol/l glucose with added insulin 
Values shown are means -t SE (8 experimental observations) and are expressed as pmol/lOO~g 
protein 
25 mmol/l glucose. A dose-response curve for this 
effect is shown in fig. 1, indicating the effect to be 
near maximal within the range of physiological in- 
sulin concentrations. Incubations were continued 
at 0.7 nmol/l insulin. The increase in myo-inositol 
uptake was significantly reduced by concurrent in- 
cubation with ouabain, pyrithiamine or amiloride. 
Ouabain, but not pyrithiamine or amiloride, also 
significantly reduced myo-inositol uptake in non- 
insulin-stimulated cells. A significant increase in 
myo-inositol uptake was seen when the Naf 
ionophores monensin and veratridine were present 
during the uptake experiment. The effect was most 
marked, however, followed pre-treatment with 
veratridine. This significant increase in myo- 
inositol uptake was partially inhibited by ouabain 
or pyrithiamine present during the uptake period. 
3.2. Cellular 22Na+ uptake 
In cells which had been incubated with 22Na+ for 
4 h in the presence of 5.6 or 25 mmol/l glucose, 
the net cellular 2ZNa+ was 5.77 & 0.7 and 5.42 f 
0.2 nmol/lOO pg protein, respectively (no signifi- 
cant difference). At 25 mmol/l glucose, when 
0.7 nmol/l insulin was present for a final 20 mitt, 
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Fig.1. Effect of insulin on myo-inositol uptake in 
NlE-115 cells. myo-Inositol uptake was determined over 
20 min in the presence of 0.07-70 nmol/l insulin. 
Values shown are means + SE for 6 determinations at 
each point. 
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Table 2 
*‘Na+ content of NlE-115 neuroblastoma cells 
Addition **Na+ content 
(nmol/ 100 pug protein 
No added Insulin 
insulin (0.7 nmol/l) 
Nil 5.42 f 0.21 7.25 + 0.51” 
Pyrithiamine ( 10m5 M) 6.42 + 1.07 8.74 + 0.37b 
Amiloride (10m5 M) 5.41 + 1.71 5.34 + 0.56b 
Ouabain (10e4 M) 13.46 ? 1.38” 15.42 + l.76b 
Monensin ( 10m6 M) 19.76 f l.51a 
Veratridine ( 10e5 M) 12.06 f 0.87” 
Veratridine (lo-’ M); 
pre-incubation 5.92 2 1.2 
a Significantly different from cells incubated without 
added insulin 
b Significantly different from cells incubated with added 
insulin 
in the presence of external 22Na+, cellular **Na+ 
rose significantly to 7.25 f 0.5 nmol/lOO~g pro- 
tein. This effect was blocked by the concurrent 
presence of amiloride. Pyrithiamine, together with 
insulin, caused a significant increase in **Na+ con- 
t 
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Fig.2. Effect of insulin on **Na+ content of NIE-115 
cells. After incubation with **Na+ as described in section 
2, cells were incubated in **Na+-free medium for 20 min 
in the presence of 0.07-70 nmol/l insulin and in the 
presence (0) or absence (0) of 10m5 M pyrithiamine. 
Results are means for triplicate estimations within an 
experiment. 
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Fig.3. Time course of **Na+ efflux from NlE-115 cells 
pre-loaded with *‘Na+. Cells were incubated in 
**Na+-free medium, following loading with **Na+. 
**Na+ content was determined over a 20 min period in 
cells which had been pre-incubated without additions 
(0) or pre-incubated in the presence of 10m5 M 
veratridine (II). The figure indicates the effect of 10e4 M 
ouabain (0), 0.7 nmol/l insulin (A), 10m6 M monensin 
(v), or lo-’ M veratridine (H) added acutely during the 
efflux period. 
tent of cells loaded and incubated in the presence 
of **Na+. Similarly, ouabain and monensin or 
veratridine added acutely raised cellular 22Na+ 
content significantly (table 2). 
3.3. “Nat efflux from pre-loaded cells 
**Na+ efflux from pre-loaded cells was deter- 
mined by monitoring *‘Na+ content over 20 min in 
cells removed to **Na+-free buffer. Insulin pro- 
moted 22Naf loss in a dose-dependent manner, 
which was blocked by the concurrent presence of 
pyrithiamine (fig.2). Similarly, **Na+ efflux was 
greater in cells to which monensin or veratridine 
had been added for 20 min or to cells pre- 
incubated with veratridine. The loss of cellular 
**Na+ could be blocked by the concurrent presence 
of ouabain (fig.3). 
4. DISCUSSION 
Our results indicate that myo-inositol uptake 
may be altered in neuroblastoma cells by 
manipulations which alter cellular Na+ flux. A 
comparison of uptake under different experimen- 
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tal conditions permits inferences to be drawn 
about the activity of Na+,K+-ATPase. Insulin, in 
particular, altered myo-inositol uptake associated 
with a pyrithiamine-inhibitable rise in 22Na+ ef- 
flux, a strong indication of Na+,K+-ATPase ac- 
tivation. It is possible that the activation of 
insulin-stimulated Na+,K+-ATPase follows ami- 
loride-sensitive Na+/H+ exchange in the neuro- 
blastoma cell. This possibility is supported by 
experiments showing an amiloride-sensitive in- 
crease in 22Na+ content induced by insulin. 
Na+/H+ exchange has been found in a number of 
cell types and proposed to be a ubiquitous compo- 
nent of mammalian cell plasma membranes in- 
cluding neuronal cells [15-171. There is 
considerable evidence that growth factors 
stimulate the activity of Na+,K+-ATPase at the cell 
membrane secondarily to this increased Na+ entry 
into cells. 
Whether the Na+,K+-ATPase activation is 
insulin-specific in all cells remains to be deter- 
mined. Here, the insulin activation of Na+,K+- 
ATPase appears to be specific for a pyrithiamine- 
inhibitable form. Both the LY and insulin-sensitive, 
cy+ catalytic subunits of Na+,K+-ATPase have 
been described in neurones [8]. The inhibition by 
pyrithiamine of 22Na+ efflux and myo-inositol up- 
take in insulin-stimulated cells suggests the 
presence of the LY+ form in the neuroblastoma line. 
Similarly, increased Na+,K+-ATPase activity 
following Na+ influx due to veratridine would in- 
dicate that, as described for cultured skeletal mus- 
cle [12], veratridine can increase Na+,K’-ATPase 
activity by stimulated biosynthesis of Na+,K+- 
ATPase subunits. In the neuroblastoma, pyrithi- 
amine inhibition of Na+,K+-ATPase and myo- 
inositol uptake after veratridine would confirm the 
presence and activation of the my+ catalytic subunit. 
Reduction of Na+,K+-ATPase activity in 
diabetic nerve is associated with reduced myo- 
inositol uptake [ 18-201. This can be prevented and 
normal Na+ flux and nerve conduction maintained 
by myo-inositol supplementation [20] or the ad- 
ministration of an aldose reductase inhibitor, cor- 
recting the metabolic consequences of hypergly- 
caemia [6,22]. The present study indicates that in- 
sulin may also contribute to improved myo- 
inositol uptake directly by increasing Na+,K+- 
ATPase activity. 
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